Advertisement

Medical and Psychosocial Issues in Hodgkin’s Disease Survivors

  • Jon Håvard Loge
  • Stein Kaasa

Abstract

The first attempts to treat Hodgkin’s disease by radiotherapy were conducted at the beginning of the last century. The prognosis for survival was poor but slowly improved by the use of radiotherapy and some chemotherapy until 1960. For example, in 1939 a 20-year survival rate of 17% was reported.1

Keywords

Clin Oncol Late Effect Chronic Fatigue Syndrome Divorce Rate Psychosocial Issue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gilbert R. Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations, governing principles, results. Am J Roentgenol 1939;41:198–241.Google Scholar
  2. 2.
    De Vita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970;73:881–895.Google Scholar
  3. 3.
    Easson EC, Russel MH. The cure of Hodgkin’s disease. Br Med J 1963;1:1704–1707.PubMedGoogle Scholar
  4. 4.
    Easson EC. Possibilities for the cure of Hodgkin’s disease. Cancer (Phila) 1966;19:345–350.CrossRefGoogle Scholar
  5. 5.
    Wessely S, Hotopf M, Sharpe M. Chronic fatigue and its syndromes. Oxford: Oxford University Press, 1999.Google Scholar
  6. 6.
    Foss AA, Egeland T, Hansen S, Langholm R, Holte H, Kvaloy S. Hodgkin’s disease in a national and hospital population: trends over 20 years. Eur J Cancer 1997;33(14):2380–2383.CrossRefGoogle Scholar
  7. 7.
    Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 2002;13(suppl 4):147–152.PubMedGoogle Scholar
  8. 8.
    Glaser SL, Swartz WG. Time trends in Hodgkin’s disease incidence. The role of diagnostic accuracy. Cancer (Phila) 1990;66(10):2196–2204.CrossRefGoogle Scholar
  9. 9.
    Glaser SL. Recent incidence and secular trends in Hodgkin’s disease and its histologic subtypes. J Chronic Dis 1986;39(10):789–798.PubMedCrossRefGoogle Scholar
  10. 10.
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21(18):3431–3439.PubMedCrossRefGoogle Scholar
  11. 11.
    Vaughan HB, Vaughan HG, Linch DC, Anderson L. Late mortality in young BNLI patients cured of Hodgkin’s disease. Ann Oncol 1994;5(suppl 2)0:65–66.Google Scholar
  12. 12.
    The Cancer Registry of Norway. Cancer in Norway 2001. Oslo: The Cancer Registry of Norway, 2004.Google Scholar
  13. 13.
    The Cancer Registry of Norway. Cancer in Norway 1992. Oslo: The Cancer Registry of Norway, 1992.Google Scholar
  14. 14.
    Canellos GP. Primary treatment of Hodgkin’s disease. Ann Oncol 2002;13(suppl 4):153–158.PubMedGoogle Scholar
  15. 15.
    Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin’s disease. Ann Oncol 2002;13(suppl 1):112–116.PubMedGoogle Scholar
  16. 16.
    Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin’s disease: finding the balance between cure and late effects. Cancer J Sci Am 1999;5(6):325–333.PubMedGoogle Scholar
  17. 17.
    Yung L, Linch D. Hodgkin’s lymphoma. Lancet 2003;361(9361):943–951.PubMedCrossRefGoogle Scholar
  18. 18.
    Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 2002;20(8):2101–2108.PubMedCrossRefGoogle Scholar
  19. 19.
    van Rijswijk RE, Verbeek J, Haanen C, Dekker AW, van Daal WA, van Peperzeel HA. Major complications and causes of death in patients treated for Hodgkin’s disease. J Clin Oncol 1987;5(10):1624–1633.PubMedGoogle Scholar
  20. 20.
    Abrahamsen AF, Loge JH, Hannisdal E, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin’s disease. Acta Oncol 1999;38(4):511–515.PubMedCrossRefGoogle Scholar
  21. 21.
    Boivin JF, Hutchison GB, Lubin JH, Mauch P. Coronary artery disease mortality in patients treated for Hodgkin’s disease. Cancer (Phila) 1992;69(5):1241–1247.PubMedCrossRefGoogle Scholar
  22. 22.
    Cosset JM, Henry-Amar M, Pellae-Cosset B, et al. Pericarditis and myocardial infarctions after Hodgkin’s disease therapy. Int J Radiat Oncol Biol Phys 1991;21(2):447–449.PubMedGoogle Scholar
  23. 23.
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–1955.PubMedCrossRefGoogle Scholar
  24. 24.
    Sears JD, Greven KM, Ferree CR, D’Agostino RB Jr. Definitive irradiation in the treatment of Hodgkin’s disease. Analysis of outcome, prognostic factors, and long-term complications. Cancer (Phila) 1997;79(1):145–151.PubMedCrossRefGoogle Scholar
  25. 25.
    Lund MB, Ihlen H, Voss BM, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin’s disease: an echocardiographic study. Heart 1996;75(6):591–595.PubMedGoogle Scholar
  26. 26.
    Gustavsson A, Eskilsson J, Landberg T, et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol 1990;1(5):355–363.PubMedGoogle Scholar
  27. 27.
    Glanzmann C, Huguenin P, Lutolf UM, Maire R, Jenni R, Gumppenberg V. Cardiac lesions after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 1994;30(1):43–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325(9):599–605.PubMedCrossRefGoogle Scholar
  29. 29.
    Peerboom PF, Hassink EA, Melkert R, DeWit L, Nooijen WJ, Bruning PF. Thyroid function 10-18 years after mantle field irradiation for Hodgkin’s disease. Eur J Cancer 1992;28A(10):1716–1718.PubMedCrossRefGoogle Scholar
  30. 30.
    Brierley JD, Rathmell AJ, Gospodarowicz MK, et al. Late effects of treatment for early-stage Hodgkin’s disease. Br J Cancer 1998;77(8):1300–1310.PubMedGoogle Scholar
  31. 31.
    Bethge W, Guggenberger D, Bamberg M, Kanz L, Bokemeyer C. Thyroid toxicity of treatment for Hodgkin’s disease. Ann Hematol 2000;79(3):114–118.PubMedCrossRefGoogle Scholar
  32. 32.
    Mauch P, Tarbell N, Weinstein H, et al. Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988;6(10):1576–1583.PubMedGoogle Scholar
  33. 33.
    Hassink EA, Souren TS, Boersma LJ, et al. Pulmonary morbidity 10–18 years after irradiation for Hodgkin’s disease. Eur J Cancer 1993;29A(3):343–347.PubMedCrossRefGoogle Scholar
  34. 34.
    Loyer E, Fuller L, Libshitz HI, Palmer JL. Radiographic appearance of the chest following therapy for Hodgkin disease. Eur J Radiol 2000;35(2):136–148.PubMedCrossRefGoogle Scholar
  35. 35.
    Lund MB, Kongerud J, Nome O, et al. Lung function impairment in long-term survivors of Hodgkin’s disease. Ann Oncol 1995;6(5):495–501.PubMedGoogle Scholar
  36. 36.
    Koocher G, O’Malley J. The Damocles Syndrome: Psychosocial Consequences of Surviving Childhood Cancer. New York: McGraw-Hill, 1981.Google Scholar
  37. 37.
    Tross S, Holland JC. Psychological sequelae in cancer survivors. In: Holland JC, Rowland JH (eds). Handbook of Psychooncology. London: Oxford University Press, 1990:101–116.Google Scholar
  38. 38.
    Cella DF, Tross S. Psychological adjustment to survival from Hodgkin’s disease. J Consult Clin Psychol 1986;54(5):616–622.PubMedCrossRefGoogle Scholar
  39. 39.
    The Constitution of the World Health Organisation. WHO Chronicle 1947;29.Google Scholar
  40. 40.
    Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D. Psychosocial problems among survivors of Hodgkin’s disease. J Clin Oncol 1986;4(5):805–814.PubMedGoogle Scholar
  41. 41.
    Kornblith AB, Anderson J, Cella DF, et al. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer (Phila) 1992;70(8):2214–2224.PubMedCrossRefGoogle Scholar
  42. 42.
    van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin’s disease. Ann Oncol 1994;5(2):153–158.PubMedGoogle Scholar
  43. 43.
    Norum J, Wist EA. Quality of life in survivors of Hodgkin’s disease. Qual Life Res 1996;5(3):367–374.PubMedCrossRefGoogle Scholar
  44. 44.
    Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequelae in Hodgkin’s disease survivors: a French populationbased case-control study. J Clin Oncol 1996;14(9):2444–2453.PubMedGoogle Scholar
  45. 45.
    Aaronson NK, Cull A, Kaasa S. The EORTC modular approach to quality of life assessment in oncology. Int J Ment Health 1994;23:75–96.Google Scholar
  46. 46.
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11(3):570–579.PubMedGoogle Scholar
  47. 47.
    Ware JE. The SF-36 health survey. In: Spilker B (ed). Quality of Life and Pharmaeconomics in Clinical Trials. Philadelphia: Lippincott-Raven, 1996:337–346.Google Scholar
  48. 48.
    Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 1998;26(4):250–258.PubMedGoogle Scholar
  49. 49.
    Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin’s disease survivors: a comparative study with general population norms. Ann Oncol 1999;10(1):71–77.PubMedCrossRefGoogle Scholar
  50. 50.
    Bloom JR, Gorsky RD, Fobair P, et al. Physical performance at work and at leisure: validation of a measure of biological energy in survivors of Hodgkin’s disease. J Psychosocial Oncol 1990;8(1):49–63.CrossRefGoogle Scholar
  51. 51.
    Bloom JR, Fobair P, Gritz E, et al. Psychosocial outcomes of cancer: a comparative analysis of Hodgkin’s disease and testicular cancer. J Clin Oncol 1993;11(5):979–988.PubMedGoogle Scholar
  52. 52.
    Greil R, Holzner B, Kemmler G, et al. Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin’s disease from 1969 to 1994. Eur J Cancer 1999;35(5):698–706.PubMedCrossRefGoogle Scholar
  53. 53.
    Olweny CL, Juttner CA, Rofe P, et al. Long-term effects of cancer treatment and consequences of cure: cancer survivors enjoy quality of life similar to their neighbours. Eur J Cancer 1993;29A(6):826–830.PubMedCrossRefGoogle Scholar
  54. 54.
    Gil-Fernandez J, Ramos C, Tamayo T, et al. Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin’s disease: results of a controlled pilot study. Ann Hematol 2003;82(1):14–18.PubMedGoogle Scholar
  55. 55.
    Knobel H, Havard LJ, Brit LM, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001;19(13):3226–3233.PubMedGoogle Scholar
  56. 56.
    Cameron CL, Cella D, Herndon JE, et al. Persistent symptoms among survivors of Hodgkin’s disease: an explanatory model based on classical conditioning. Health Psychol 2001;20(1):71–75.PubMedCrossRefGoogle Scholar
  57. 57.
    Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16(1):139–144.PubMedGoogle Scholar
  58. 58.
    Lee JQ, Simmonds MJ, Wang XS, Novy DM. Differences in physical performance between men and women with and without lymphoma. Arch Phys Med Rehabil 2003;84(12):1747–1752.PubMedCrossRefGoogle Scholar
  59. 59.
    Devlen J, Maguire P, Phillips P, Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 1987;295(6604):955–957.Google Scholar
  60. 60.
    Devlen J, Maguire P, Phillips P, Crowther D, Chambers H. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987;295(6604):953–954.CrossRefGoogle Scholar
  61. 61.
    Lewis G, Wessely S. The epidemiology of fatigue: more questions than answers. J Epidemiol Community Health 1992;46(2):92–97.PubMedGoogle Scholar
  62. 62.
    Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based study of fatigue and psychological distress [see comments]. BMJ 1994;308(6931):763–766.PubMedGoogle Scholar
  63. 63.
    Ganz PA, Moinpour CM, Pauler DK, et al. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol 2003;21(18):3512–3519.PubMedCrossRefGoogle Scholar
  64. 64.
    Kornblith AB, Herndon JE, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol 1998;9(3):297–306.PubMedCrossRefGoogle Scholar
  65. 65.
    Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999;17(1):253–261.PubMedGoogle Scholar
  66. 66.
    Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin’s lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39(15):2179–2186.PubMedCrossRefGoogle Scholar
  67. 67.
    Wettergren L, Bjorkholm M, Axdorph U, Bowling A, Langius-Eklof A. Individual quality of life in long-term survivors of Hodgkin’s lymphoma: a comparative study. Qual Life Res 2003;12(5):545–554.PubMedCrossRefGoogle Scholar
  68. 68.
    Fossa SD, Dahl AA, Loge JH. Fatigue, anxiety and depression and mental health in long-term survivors of testicular cancer. J Clin Oncol 2003;21:1249–1254.PubMedCrossRefGoogle Scholar
  69. 69.
    Loge JH, Abrahamsen AF, Ekeberg, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin’s disease survivors. J Pain Symptom Manag 2000;19(2):91–99.CrossRefGoogle Scholar
  70. 70.
    Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998;6(2):101–108.PubMedCrossRefGoogle Scholar
  71. 71.
    Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer (Phila) 2003;97(11):2919–2925.CrossRefGoogle Scholar
  72. 72.
    Knobel H, Loge JH, Nordoy T, et al. High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manag 2000;19(6):446–456.CrossRefGoogle Scholar
  73. 73.
    Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. Psychological symptoms, somatic symptoms, and psychiatric disorder in chronic fatigue and chronic fatigue syndrome: a prospective study in the primary care setting. Am J Psychiatry 1996;153(8):1050–1059.PubMedGoogle Scholar
  74. 74.
    Loge JH, Abrahamsen AF, Ekeberg O, Hannisdal E, Kaasa S. Psychological distress after cancer cure: a survey of 459 Hodgkin’s disease survivors. Br J Cancer 1997;76(6):791–796.PubMedGoogle Scholar
  75. 75.
    Herrmann C. International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results. J Psychosom Res 1997;42(1):17–41.PubMedCrossRefGoogle Scholar
  76. 76.
    Minaire P. Disease, illness and health: theoretical models of the disablement process. Bull WHO 1992;70(3):373–379.PubMedGoogle Scholar
  77. 77.
    Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaloy S. Sociomedical situation for long-term survivors of Hodgkin’s disease: a survey of 459 patients treated at one institution. Eur J Cancer 1998;34(12):1865–1870.PubMedCrossRefGoogle Scholar
  78. 78.
    Ringdal GI, Ringdal K, Jordhoy MS, Ahlner-Elmqvist M, Jannert M, Kaasa S. Health-related quality of life (HRQOL) in family members of cancer victims: results from a longitudinal intervention study in Norway and Sweden. Palliat Med 2004;18(2):108–120.PubMedCrossRefGoogle Scholar
  79. 79.
    Oldervoll LM, Kaasa S, Knobel H, Loge JH. Exercise reduces fatigue in chronic fatigued Hodgkin’s disease survivors: results from a pilot study. Eur J Cancer 2003;39(1):57–63.PubMedCrossRefGoogle Scholar
  80. 80.
    Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001;286(11):1360–1368.PubMedCrossRefGoogle Scholar
  81. 81.
    Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center community clinical oncology program. J Clin Oncol 2003;21(24):4635–4641.PubMedCrossRefGoogle Scholar
  82. 82.
    Yehuda R. Post-traumatic stress disorder. N Engl J Med 2002;346(2):108–114.PubMedCrossRefGoogle Scholar
  83. 83.
    Gill D, Hatcher S. Antidepressants for depression in people with physical illness. Cochrane Database Syst Rev 2000;2:CD001312.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Jon Håvard Loge
    • 1
    • 2
  • Stein Kaasa
    • 3
    • 4
  1. 1.Department of Behavioral Sciences in MedicineUniversity of OsloOslo
  2. 2.Centre for Palliative MedicineUlleval University HospitalOsloNorway
  3. 3.Department of Cancer Research and Molecular Medicine, Faculty of MedicineThe Norwegian University of Science and TechnologyNorway
  4. 4.Palliative Care UnitSt. Olavs HospitalTrondheimNorway

Personalised recommendations